|Bid||1,705.00 x 0|
|Ask||1,705.50 x 0|
|Day's range||1,673.00 - 1,716.00|
|52-week range||1,376.00 - 1,998.40|
|Beta (3Y monthly)||-0.13|
|PE ratio (TTM)||21.36|
|Earnings date||20 Feb 2020|
|Forward dividend & yield||0.28 (1.72%)|
|1y target est||18.49|
I think these two FTSE 100 (INDEXFTSE:UKX) stocks could offer high total return potential that may boost your retirement savings prospects.
A federal appeals court on Thursday declared unconstitutional the structure of the federal tribunal that reviews the validity of patents, but said the problem could be fixed by severing a law restricting the removal of its judges. The decision by the U.S. Federal Circuit Court of Appeals in Washington, D.C., which reviews patent litigation, likely reduces the threat that scores of decisions by the Patent Trial and Appeal Board could be set aside. In a 3-0 ruling, the court said its decision would be "limited" to cases in which the board had issued final written decisions, and litigants appealed the constitutionality of how its judges were appointed.
Investing.com -- Here's a roundup of regulatory news releases from the London Stock Exchange on Thursday, 31st October. Please refresh for updates.
European shares broke a three-day run of losses on Monday, as investors stuck to hopes that Britain will avoid a disorderly exit from the European Union, while positive corporate updates and comments on U.S.-China trade talks added to the upbeat mood. The pan-European STOXX 600 index ended the session 0.6% higher, barely budging on news House of Commons speaker John Bercow refused to allow a vote on Prime Minister Boris Johnson's Brexit divorce deal, saying the same issue had been discussed on Saturday.
UK midcaps closed the session with modest gains on Monday on hopes that a no-deal Brexit will be avoided, even though uncertainties persisted as lawmakers forced Prime Minister Boris Johnson to seek another extension from the European Union. The domestically focused FTSE 250 added 0.4% on Monday, while the exporter-heavy FTSE 100 edged 0.2% higher, lagging its European counterpart as the pound strengthened.
A daily overview of the top business, market, and economic stories to watch in the UK, Europe, and abroad.
Smith+Nephew Plc Chief Executive Namal Nawana is stepping down after just 17 months in the role after becoming dissatisfied with his salary at the medical device maker. The company said Nawana, who will be replaced by former Roche Diagnostics head Roland Diggelmann, was leaving to pursue opportunities outside the United Kingdom and his departure was a mutual decision. "There appears to be a pretty simple reason Nawana is leaving – pay," AJ Bell investment director Russ Mould said.
Peter Stephens thinks these two FTSE 100 (INDEXFTSE:UKX) stocks could offer higher returns than gold over the long run.
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses...
The former chief business officer of U.S. biotechnology company Osiris Therapeutics Inc has agreed to pay a $40,000 civil penalty for lying to auditors, the Securities and Exchange Commission said on Thursday. The SEC had alleged that Bobby Dwayne Montgomery prompted Osiris to book fake revenue and give false information to auditors. Montgomery agreed to a judgment that enjoins him from future violations of securities law, the SEC said in a statement.
Stockopedia’s own data points to a jarringly simple stock market truth amidst the daily whirlwind of financial data: share prices that have gone up tend to kee8230;
Smith & Nephew plc (LON:SN.) is about to trade ex-dividend in the next 2 days. If you purchase the stock on or after...
Is Smith & Nephew plc (LON:SN.) a good dividend stock? How can we tell? Dividend paying companies with growing...
Examining how Smith & Nephew plc (LON:SN.) is performing as a company requires looking at more than just a years...